The use of pulmonary clearance medications in the acutely ill patient

Expert Rev Respir Med. 2017 Oct;11(10):815-826. doi: 10.1080/17476348.2017.1358089. Epub 2017 Aug 18.

Abstract

Retention of airway secretions occurs in disease, leading to airway plugging, atelectasis, and worsened respiratory mechanics, making airway clearance an important therapeutic target. Areas covered: Many medications designed to enhance clearance of airway secretions are available. We will review the medications available to enhance airway clearance, their mechanisms of action, and the evidence available for their use in acutely ill patients. Expert commentary: In the cystic fibrosis (CF) population, beneficial effects have been shown in pulmonary function with the use of some of these agents. In the non-CF population, there is limited evidence regarding these medications. While some studies have found benefit, the quality of evidence is low, making it difficult to draw conclusions. While certain patients may derive benefit, the general use of these medications in acutely ill patients without CF cannot be recommended at this time.

Keywords: Airway secretions; hypertonic saline; mucolytics; mucus; pulmonary clearance; sputum.

Publication types

  • Review

MeSH terms

  • Acetylcysteine / therapeutic use
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / physiopathology
  • Deoxyribonuclease I / therapeutic use
  • Expectorants / therapeutic use*
  • Heparin / therapeutic use
  • Humans
  • Lung / physiopathology
  • Mannitol / therapeutic use
  • Mucociliary Clearance / physiology*
  • Recombinant Proteins / therapeutic use
  • Saline Solution, Hypertonic / therapeutic use
  • Smoke Inhalation Injury / drug therapy

Substances

  • Expectorants
  • Recombinant Proteins
  • Saline Solution, Hypertonic
  • Mannitol
  • Heparin
  • Deoxyribonuclease I
  • dornase alfa
  • Acetylcysteine